History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story
History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story
复制标题
DOI：
10.1016/j.juro.2007.08.122
复制
发表时间：
2008-01-01
影响因子：
6.6
通讯作者：
Moralest, Alvaro
中科院分区：
文献类型：
--
作者：
Herr, Harry W.;Moralest, Alvaro
目的：我们回顾了卡介苗如何演变成为浅表性膀胱癌的标准疗法。材料和方法：我们回顾了历史文献，描述了卡介苗作为抗癌剂的起源及其作为最有效的免疫疗法用于对抗人类肿瘤的独特成功。结果：结核病和癌症之间的联系，以及卡介苗引起免疫反应，抑制实验动物模型中肿瘤生长的证明，导致的临床试验表明，膀胱内卡介苗根除和预防浅表性膀胱tumors.Conclusions复发：在过去的30年卡介苗治疗仍然是最有效的局部治疗浅表性膀胱癌，成功的转化医学在泌尿外科的杰出例子。
Purpose: We review how the bacillus Calmette-Guerin vaccine evolved to become standard therapy for superficial bladder cancer.Materials and Methods: We reviewed the historical literature describing the origin of the bacillus Calmette-Guerin vaccine as an anticancer agent and its singular success as the most effective immunotherapy used against a human neoplasm.Results: The association between tuberculosis and cancer, and the demonstration that bacillus Calmette-Guerin invoked immunological reactivity, inhibiting tumor growth in experimental animal models, led to clinical trials showing that intravesical bacillus Calmette-Guerin eradicated and prevented recurrence of superficial bladder tumors.Conclusions: For the last 3 decades bacillus Calmette-Guerin therapy has remained the most effective local therapy for superficial bladder cancer, an outstanding example of successful translational medicine in urology.